Taiwan hits cancer drug companies with fines
Taiwan’s competition authority has fined a pair of pharmaceutical companies more than €8 million for entering into an anticompetitive agreement for the exclusive distribution of colorectal cancer drugs.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.